{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:17:03Z","timestamp":1789168623374,"version":"build-2803163510"},"reference-count":73,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FISS-21-RD21\/0002\/0041"],"award-info":[{"award-number":["FISS-21-RD21\/0002\/0041"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["AEA-FIO-010322"],"award-info":[{"award-number":["AEA-FIO-010322"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["BTI23002"],"award-info":[{"award-number":["BTI23002"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIO-24001"],"award-info":[{"award-number":["FIO-24001"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Asociaci\u00f3n Espa\u00f1ola de Aniridia","award":["FISS-21-RD21\/0002\/0041"],"award-info":[{"award-number":["FISS-21-RD21\/0002\/0041"]}]},{"name":"Asociaci\u00f3n Espa\u00f1ola de Aniridia","award":["AEA-FIO-010322"],"award-info":[{"award-number":["AEA-FIO-010322"]}]},{"name":"Asociaci\u00f3n Espa\u00f1ola de Aniridia","award":["BTI23002"],"award-info":[{"award-number":["BTI23002"]}]},{"name":"Asociaci\u00f3n Espa\u00f1ola de Aniridia","award":["FIO-24001"],"award-info":[{"award-number":["FIO-24001"]}]},{"name":"Fundaci\u00f3n Eduardo Anitua","award":["FISS-21-RD21\/0002\/0041"],"award-info":[{"award-number":["FISS-21-RD21\/0002\/0041"]}]},{"name":"Fundaci\u00f3n Eduardo Anitua","award":["AEA-FIO-010322"],"award-info":[{"award-number":["AEA-FIO-010322"]}]},{"name":"Fundaci\u00f3n Eduardo Anitua","award":["BTI23002"],"award-info":[{"award-number":["BTI23002"]}]},{"name":"Fundaci\u00f3n Eduardo Anitua","award":["FIO-24001"],"award-info":[{"award-number":["FIO-24001"]}]},{"name":"Fundaci\u00f3n de Investigaci\u00f3n Oftalmol\u00f3gica","award":["FISS-21-RD21\/0002\/0041"],"award-info":[{"award-number":["FISS-21-RD21\/0002\/0041"]}]},{"name":"Fundaci\u00f3n de Investigaci\u00f3n Oftalmol\u00f3gica","award":["AEA-FIO-010322"],"award-info":[{"award-number":["AEA-FIO-010322"]}]},{"name":"Fundaci\u00f3n de Investigaci\u00f3n Oftalmol\u00f3gica","award":["BTI23002"],"award-info":[{"award-number":["BTI23002"]}]},{"name":"Fundaci\u00f3n de Investigaci\u00f3n Oftalmol\u00f3gica","award":["FIO-24001"],"award-info":[{"award-number":["FIO-24001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Congenital aniridia is a rare bilateral ocular malformation characterized by the partial or complete absence of the iris and is frequently associated with various anomalies, including keratopathy, cataract, glaucoma, and foveal and optic nerve hypoplasia. Additionally, nearly 50% of individuals with congenital aniridia experience symptoms of ocular dryness. Traditional treatment encompasses artificial tears and autologous serum. This study aimed to assess the effectiveness and safety of using platelet rich in growth factors (PRGF) plasma in patients with congenital aniridia and ocular dryness symptoms. Methods: The included patients underwent two cycles of a 3-month PRGF treatment. At 6 months, symptomatology was evaluated using the OSDI and SANDE questionnaires, and ocular surface parameters were analyzed. Results: The OSDI and SANDE values for frequency and severity demonstrated statistically significant improvements (p &lt; 0.05). Ocular redness, corneal damage (corneal staining), and tear volume (Schirmer test) also exhibited statistically significant improvements (p &lt; 0.05). No significant changes were observed in visual acuity or in the grade of meibomian gland loss. Conclusion: The use of PRGF in patients with congenital aniridia and ocular dryness symptoms led to significant improvements in symptomatology, ocular redness, and ocular damage. No adverse effects were observed during the use of PRGF.<\/jats:p>","DOI":"10.3390\/diseases12040076","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T03:29:04Z","timestamp":1712806144000},"page":"76","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and Safety of Plasma Rich in Growth Factor in Patients with Congenital Aniridia and Dry Eye Disease"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5306-1921","authenticated-orcid":false,"given":"Javier","family":"Lozano-Sanroma","sequence":"first","affiliation":[{"name":"Instituto Universitario Fern\u00e1ndez-Vega, Fundaci\u00f3n de Investigaci\u00f3n Oftalmol\u00f3gica, 33012 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4976-3792","authenticated-orcid":false,"given":"Alberto","family":"Barros","sequence":"additional","affiliation":[{"name":"Instituto Universitario Fern\u00e1ndez-Vega, Fundaci\u00f3n de Investigaci\u00f3n Oftalmol\u00f3gica, 33012 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6051-9240","authenticated-orcid":false,"given":"Ignacio","family":"Alcalde","sequence":"additional","affiliation":[{"name":"Instituto Universitario Fern\u00e1ndez-Vega, Fundaci\u00f3n de Investigaci\u00f3n Oftalmol\u00f3gica, 33012 Oviedo, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), Universidad de Oviedo, 33011 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1885-2335","authenticated-orcid":false,"given":"Rosa","family":"Alvarado-Villacorta","sequence":"additional","affiliation":[{"name":"Instituto Universitario Fern\u00e1ndez-Vega, Fundaci\u00f3n de Investigaci\u00f3n Oftalmol\u00f3gica, 33012 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"S\u00e1nchez-\u00c1vila","sequence":"additional","affiliation":[{"name":"Regenerative Medicine Laboratory, Biotechnology Institute (BTI), 01007 Vitoria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4009-7228","authenticated-orcid":false,"given":"Juan","family":"Queiruga-Pi\u00f1eiro","sequence":"additional","affiliation":[{"name":"Instituto Universitario Fern\u00e1ndez-Vega, Fundaci\u00f3n de Investigaci\u00f3n Oftalmol\u00f3gica, 33012 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Fern\u00e1ndez-Vega","family":"Cueto","sequence":"additional","affiliation":[{"name":"Instituto Universitario Fern\u00e1ndez-Vega, Fundaci\u00f3n de Investigaci\u00f3n Oftalmol\u00f3gica, 33012 Oviedo, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), Universidad de Oviedo, 33011 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8386-5303","authenticated-orcid":false,"given":"Eduardo","family":"Anitua","sequence":"additional","affiliation":[{"name":"Regenerative Medicine Laboratory, Biotechnology Institute (BTI), 01007 Vitoria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3740-3754","authenticated-orcid":false,"given":"Jes\u00fas","family":"Merayo-Lloves","sequence":"additional","affiliation":[{"name":"Instituto Universitario Fern\u00e1ndez-Vega, Fundaci\u00f3n de Investigaci\u00f3n Oftalmol\u00f3gica, 33012 Oviedo, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), Universidad de Oviedo, 33011 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,11]]},"reference":[{"key":"ref_1","unstructured":"Moosajee, M., Hingorani, M., and Moore, A.T. (1993). PAX6-Related Aniridia, University of Washington, Seattle."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/bjophthalmol-2017-310927","article-title":"Meibomian Gland Dysfunction and Keratopathy Are Associated with Dry Eye Disease in Aniridia","volume":"103","author":"Landsend","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"ref_3","first-page":"435","article-title":"Manejo Terap\u00e9utico de La Queratopat\u00eda Asociada a Aniridia Cong\u00e9nita","volume":"81","author":"Rivas","year":"2006","journal-title":"Arch. Soc. Esp. Oftalmol."},{"key":"ref_4","unstructured":"Orphanet (2024, February 01). Available online: https:\/\/www.orpha.net\/consor4.01\/www\/cgi-bin\/Disease_Search.php?lng=ES&data_id=19593&Disease_Disease_Search_diseaseGroup=aniridia&Disease_Disease_Search_diseaseType=Pat&Enfermedad(es)\/grupo%20de%20enfermedades=Aniridia-aislada&title=Aniridia%20aislada&search=Disease_Search_Simple."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1167\/iovs.08-2827","article-title":"Detailed Ophthalmologic Evaluation of 43 Individuals with PAX6 Mutations","volume":"50","author":"Hingorani","year":"2009","journal-title":"Investig. Opthalmology Vis. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1755-3768.2008.01309.x","article-title":"Epidemiology of Aniridia in Sweden and Norway","volume":"86","author":"Iggman","year":"2008","journal-title":"Acta Ophthalmol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0161-6420(02)01451-3","article-title":"Management of Aniridic Keratopathy with Keratolimbal Allograft: A Limbal Stem Cell Transplantation Technique","volume":"110","author":"Holland","year":"2003","journal-title":"Ophthalmology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0161-6420(96)30737-9","article-title":"Limbal Transplantation","volume":"103","author":"Tan","year":"1996","journal-title":"Ophthalmology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.survophthal.2021.02.011","article-title":"Congenital Aniridia\u2014A Comprehensive Review of Clinical Features and Therapeutic Approaches","volume":"66","author":"Landsend","year":"2021","journal-title":"Surv. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jtos.2015.10.003","article-title":"Congenital Aniridia and the Ocular Surface","volume":"14","author":"Ihnatko","year":"2016","journal-title":"Ocul. Surf."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1586\/17469899.2016.1152182","article-title":"Congenital Aniridia: Etiology, Manifestations and Management","volume":"11","author":"Samant","year":"2016","journal-title":"Expert Rev. Ophthalmol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/archopht.1975.01010020815015","article-title":"Clinical Experience with a Mobile Ocular Perfusion Pump","volume":"93","author":"Ralph","year":"1975","journal-title":"Arch. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ophtha.2007.03.087","article-title":"Autologous Serum Eyedrops in the Treatment of Aniridic Keratopathy","volume":"115","author":"Rivas","year":"2008","journal-title":"Ophthalmology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e605","DOI":"10.1111\/aos.12710","article-title":"Autologous Serum and Plasma Rich in Growth Factors in Ophthalmology: Preclinical and Clinical Studies","volume":"93","author":"Anitua","year":"2015","journal-title":"Acta Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.exer.2013.12.005","article-title":"Effects of Heat-Treatment on Plasma Rich in Growth Factors-Derived Autologous Eye Drop","volume":"119","author":"Anitua","year":"2014","journal-title":"Exp. Eye Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6066","DOI":"10.1167\/iovs.11-7302","article-title":"Plasma Rich in Growth Factors (PRGF-Endoret) Stimulates Proliferation and Migration of Primary Keratocytes and Conjunctival Fibroblasts and Inhibits and Reverts TGF-\u03921\u2013Induced Myodifferentiation","volume":"52","author":"Anitua","year":"2011","journal-title":"Investig. Opthalmology Vis. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/ICO.0b013e31803dcda2","article-title":"Interleukin-6 and Tumor Necrosis Factor-\u03b1 Levels in Tears of Patients With Dry Eye Syndrome","volume":"26","author":"Yoon","year":"2007","journal-title":"Cornea"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1076\/ceyr.19.3.201.5309","article-title":"Altered Cytokine Balance in the Tear Fluid and Conjunctiva of Patients with Sjogren\u2019s Syndrome Keratoconjunctivitis Sicca","volume":"19","author":"Pflugfelder","year":"1999","journal-title":"Curr. Eye Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1167\/iovs.18-24027","article-title":"The Level of Inflammatory Tear Cytokines Is Elevated in Congenital Aniridia and Associated with Meibomian Gland Dysfunction","volume":"59","author":"Landsend","year":"2018","journal-title":"Investig. Opthalmology Vis. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.tripleo.2005.03.007","article-title":"The Effect of Platelet-Rich Plasma on the Cellular Response of Rat Bone Marrow Cells in Vitro","volume":"100","author":"Ogino","year":"2005","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1097\/ICO.0b013e31820d86d6","article-title":"Efficacy of Plasma Rich in Growth Factors for the Treatment of Dry Eye","volume":"30","author":"Morales","year":"2011","journal-title":"Cornea"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Barros, A., Lozano-Sanroma, J., Queiruga-Pi\u00f1eiro, J., Fern\u00e1ndez-Vega Cueto, L., Anitua, E., Alcalde, I., and Merayo-Lloves, J. (2023). Recovery of Corneal Innervation after Treatment in Dry Eye Disease: A Confocal Microscopy Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12051841"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/jop.2016.0166","article-title":"The Effect of Immunologically Safe Plasma Rich in Growth Factor Eye Drops in Patients with Sj\u00f6gren Syndrome","volume":"33","author":"Riestra","year":"2017","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/1120672118818943","article-title":"Plasma Rich in Growth Factors for the Treatment of Dry Eye from Patients with Graft versus Host Diseases","volume":"30","author":"Muruzabal","year":"2020","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Lozano-Sanroma, J., Barros, A., Alcalde, I., S\u00e1nchez-\u00c1vila, R.M., Queiruga-Pi\u00f1eiro, J., Fern\u00e1ndez-Vega Cueto, L., and Merayo-Lloves, J. (2023). Impact of Plasma Rich in Growth Factors (PRGF) Eye Drops on Ocular Redness and Symptomatology in Patients with Dry Eye Disease. Medicina, 59.","DOI":"10.3390\/medicina59050928"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000444496","article-title":"Safety and Efficacy of Autologous Plasma Rich in Growth Factors Eye Drops for the Treatment of Evaporative Dry Eye","volume":"56","author":"Riestra","year":"2016","journal-title":"Ophthalmic Res."},{"key":"ref_27","first-page":"291","article-title":"Keratopathy, Cataract, and Dry Eye in a Survey of Aniridia Subjects","volume":"9","author":"Shiple","year":"2015","journal-title":"Clin. Ophthalmol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.exer.2015.02.016","article-title":"Plasma Rich in Growth Factors (PRGF) Eye Drops Stimulates Scarless Regeneration Compared to Autologous Serum in the Ocular Surface Stromal Fibroblasts","volume":"135","author":"Anitua","year":"2015","journal-title":"Exp. Eye Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/09273940701486803","article-title":"Ocular Surface Disease Index for the Diagnosis of Dry Eye Syndrome","volume":"15","author":"Aydin","year":"2007","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S1542-0124(12)70053-8","article-title":"Development and Validation of a Short Global Dry Eye Symptom Index","volume":"5","author":"Schaumberg","year":"2007","journal-title":"Ocul. Surf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/j.clae.2012.08.058","article-title":"Objective Classification and Documentation of Bulbar Redness Using a Corneal Topographer","volume":"35","author":"Jerchel","year":"2012","journal-title":"Contact Lens Anterior Eye"},{"key":"ref_32","first-page":"340","article-title":"Automated Measurement of Bulbar Redness","volume":"43","author":"Fieguth","year":"2002","journal-title":"Investig. Opthalmology Vis. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1167\/iovs.13-12217","article-title":"The Ocular Redness Index: A Novel Automated Method for Measuring Ocular Injection","volume":"54","author":"Amparo","year":"2013","journal-title":"Investig. Opthalmology Vis. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/OPX.0000000000000643","article-title":"Assessment of Bulbar Redness with a Newly Developed Keratograph","volume":"92","author":"Wu","year":"2015","journal-title":"Optom. Vis. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ophtha.2019.09.034","article-title":"PAX6 Mutational Status Determines Aniridia-Associated Keratopathy Phenotype","volume":"127","author":"Lagali","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Tsubota, K., Pflugfelder, S.C., Liu, Z., Baudouin, C., Kim, H.M., Messmer, E.M., Kruse, F., Liang, L., Carreno-Galeano, J.T., and Rolando, M. (2020). Defining Dry Eye from a Clinical Perspective. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239271"},{"key":"ref_37","first-page":"478","article-title":"Comparison of the Schirmer I Test with and without Topical Anesthesia for Diagnosing Dry Eye","volume":"5","author":"Li","year":"2012","journal-title":"Int. J. Ophthalmol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/bjo.83.1.89","article-title":"Diseases Associated with Ocular Surface Abnormalities: The Importance of Reflex Tearing","volume":"83","author":"Tsubota","year":"1999","journal-title":"Br. J. Ophthalmol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00003226-198801000-00012","article-title":"Impression Cytology","volume":"7","author":"Nelson","year":"1988","journal-title":"Cornea"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"103155","DOI":"10.1016\/j.transci.2021.103155","article-title":"Metabolomics Comparison of Cord and Peripheral Blood-Derived Serum Eye Drops for the Treatment of Dry Eye Disease","volume":"60","author":"Quartieri","year":"2021","journal-title":"Transfus. Apher. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/01.ico.0000183484.85636.b6","article-title":"Application of Umbilical Cord Serum Eyedrops for the Treatment of Dry Eye Syndrome","volume":"25","author":"Yoon","year":"2006","journal-title":"Cornea"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Galbis-Estrada, C., Martinez-Castillo, S., Morales, J.M., Vivar-Llopis, B., Monle\u00f3n, D., D\u00edaz-Llopis, M., and Pinazo-Dur\u00e1n, M.D. (2014). Differential Effects of Dry Eye Disorders on Metabolomic Profile by 1H Nuclear Magnetic Resonance Spectroscopy. BioMed Res. Int., 2014.","DOI":"10.1155\/2014\/542549"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Yazdani, M., Elgst\u00f8en, K.B.P., Rootwelt, H., Shahdadfar, A., Utheim, \u00d8.A., and Utheim, T.P. (2019). Tear Metabolomics in Dry Eye Disease: A Review. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20153755"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.transci.2017.07.023","article-title":"Blood Derived Eye Drops for the Treatment of Cornea and Ocular Surface Diseases","volume":"56","author":"Giannaccare","year":"2017","journal-title":"Transfus. Apher. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Pan, Q., Angelina, A., Marrone, M., Stark, W.J., and Akpek, E.K. (2017). Autologous Serum Eye Drops for Dry Eye. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD009327.pub3"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0161-6420(99)90412-8","article-title":"Treatment of Persistent Corneal Epithelial Defect by Autologous Serum Application","volume":"106","author":"Tsubota","year":"1999","journal-title":"Ophthalmology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ajo.2007.03.016","article-title":"Comparison of Autologous Serum and Umbilical Cord Serum Eye Drops for Dry Eye Syndrome","volume":"144","author":"Yoon","year":"2007","journal-title":"Am. J. Ophthalmol."},{"key":"ref_48","unstructured":"(2024, April 10). Informe de La Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios Sobre El Uso de Plasma Rico En Plaquetas. Available online: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/medSituacionesEspeciales\/docs\/PRP-AEMPS-DEF-mayo13.pdf."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/0363546517746112","article-title":"Concentrations of Blood Components in Commercial Platelet-Rich Plasma Separation Systems: A Review of the Literature","volume":"47","author":"Oudelaar","year":"2019","journal-title":"Am. J. Sports Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.bbmt.2016.05.023","article-title":"A Single-Center Pilot Prospective Study of Topical Application of Platelet-Derived Eye Drops for Patients with Ocular Chronic Graft-versus-Host Disease","volume":"22","author":"Zallio","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000100933","article-title":"Symptomatic Dry Eye Treatment with Autologous Platelet-Rich Plasma","volume":"39","author":"Alio","year":"2007","journal-title":"Ophthalmic Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.5935\/0034-7280.20170067","article-title":"The Use of Platelet Rich-Plasma in Ophthalmology: A Literature Review","volume":"76","author":"Ribeiro","year":"2017","journal-title":"Rev. Bras. Oftalmol."},{"key":"ref_53","first-page":"e170","article-title":"Efficacy and Safety of Treatment of Hyposecretory Dry Eye with Platelet-Rich Plasma","volume":"97","author":"Molina","year":"2019","journal-title":"Acta Ophthalmol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/ICO.0b013e3181a81820","article-title":"Plasma Rich in Growth Factors as a Therapeutic Agent for Persistent Corneal Epithelial Defects","volume":"29","author":"Morales","year":"2010","journal-title":"Cornea"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000439280","article-title":"Autologous Plasma Rich in Growth Factors Eyedrops in Refractory Cases of Ocular Surface Disorders","volume":"55","author":"Sanchez","year":"2016","journal-title":"Ophthalmic Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1167\/iovs.11-7340","article-title":"In Vitro Effects of Three Blood Derivatives on Human Corneal Epithelial Cells","volume":"53","author":"Freire","year":"2012","journal-title":"Investig. Opthalmology Vis. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Wr\u00f3bel-Dudzi\u0144ska, D., Przekora, A., Kazimierczak, P., \u0106wikli\u0144ska-Haszcz, A., Kosior-Jarecka, E., and \u017barnowski, T. (2023). The Comparison between the Composition of 100% Autologous Serum and 100% Platelet-Rich Plasma Eye Drops and Their Impact on the Treatment Effectiveness of Dry Eye Disease in Primary Sjogren Syndrome. J Clin Med, 12.","DOI":"10.3390\/jcm12093126"},{"key":"ref_58","unstructured":"(2023, August 16). Comparison of the Healing Properties on Corneal Cells of Growth Factor-Enriched Plasma and Autologous Serum From Aniridia Patients (CICASAND), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05400590?cond=Congenital%20Aniridia&page=1&rank=2."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and Validity of the Ocular Surface Disease Index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch. Ophthalmol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/archophthalmol.2009.356","article-title":"Minimal Clinically Important Difference for the Ocular Surface Disease Index","volume":"128","author":"Miller","year":"2010","journal-title":"Arch. Ophthalmol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.ajem.2019.158489","article-title":"How Much Change in Pain Score Does Really Matter to Patients?","volume":"38","author":"Bahreini","year":"2020","journal-title":"Am. J. Emerg. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0196-0644(96)70226-3","article-title":"Clinical Versus Statistical Significance in the Assessment of Pain Relief","volume":"27","author":"Todd","year":"1996","journal-title":"Ann. Emerg. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.preteyeres.2012.02.003","article-title":"Ocular Surface Immunity: Homeostatic Mechanisms and Their Disruption in Dry Eye Disease","volume":"31","author":"Barabino","year":"2012","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_64","first-page":"687","article-title":"Key Factors in the Subjective and Objective Assessment of Conjunctival Erythema","volume":"41","author":"Papas","year":"2000","journal-title":"Investig. Opthalmology Vis. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Anitua, E., de la Fuente, M., Merayo-Lloves, J., and Muruzabal, F. (2022). Optimization of a Plasma Rich in Growth Factors Membrane for the Treatment of Inflammatory Ocular Diseases. Bioengineering, 9.","DOI":"10.3390\/bioengineering9100508"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/sj.eye.6702058","article-title":"Evaluating an Impression Cytology Grading System (IC Score) in Patients with Dry Eye Syndrome","volume":"20","author":"Schwantzer","year":"2006","journal-title":"Eye"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1001\/archopht.1973.01000040105007","article-title":"Factors Affecting Tear Film Breakup in Normal Eyes","volume":"89","author":"Lemp","year":"1973","journal-title":"Arch. Ophthalmol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jtos.2021.04.011","article-title":"Clinical Practice Patterns in the Management of Dry Eye Disease: A TFOS International Survey","volume":"21","author":"Wolffsohn","year":"2021","journal-title":"Ocul. Surf."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II Definition and Classification Report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"van Setten, G.B., Baudouin, C., Horwath-Winter, J., B\u00f6hringer, D., Stachs, O., Toker, E., Al-Zaaidi, S., Benitez-Del-castillo, J.M., Beck, R., and Al-Sheikh, O. (2020). The Hylan m Study: Efficacy of 0.15% High Molecular Weight Hyaluronan Fluid in the Treatment of Severe Dry Eye Disease in a Multicenter Randomized Trial. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113536"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/bjo.86.4.418","article-title":"Prevalence of Ocular Symptoms and Signs with Preserved and Preservative Free Glaucoma Medication","volume":"86","author":"Pisella","year":"2002","journal-title":"Br. J. Ophthalmol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/112067210701700311","article-title":"Ocular Symptoms and Signs with Preserved and Preservative-Free Glaucoma Medications","volume":"17","author":"Jaenen","year":"2007","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.joco.2018.07.003","article-title":"The Impact of Topical Intraocular Pressure Lowering Medications on the Ocular Surface of Glaucoma Patients: A Review","volume":"31","author":"Asiedu","year":"2019","journal-title":"J. Curr. Ophthalmol."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/12\/4\/76\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:26:05Z","timestamp":1760106365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/12\/4\/76"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,11]]},"references-count":73,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["diseases12040076"],"URL":"https:\/\/doi.org\/10.3390\/diseases12040076","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,11]]}}}